Skip to main content
SpringerLink
Log in

Serum chromogranin A levels for the diagnosis and follow-up of well-differentiated non-functioning neuroendocrine tumors

  • Original Article
  • Published:
Tumor Biology

Abstract

Circulating chromogranin A (CgA) level is a useful marker for diagnosis and treatment efficacy monitoring of neuroendocrine tumors (NETs). To evaluate the diagnostic value of serum CgA in well-differentiated non-functioning NETs and to investigate the correlation between changes in serum CgA levels and imaging responses in patients with locally advanced or metastatic disease, 60 healthy controls and 82 patients with NETs (28 with localized NETs and 54 with advanced NETs) treated between December 2010 and November 2014 were included. CgA levels were determined by ELISA. Receiver-operating characteristic (ROC) curve analysis was used to evaluate the diagnostic sensitivity and specificity of serum CgA. Correlation between CgA levels and tumor burden was analyzed. Serial CgA measurements and tumor responses (evaluated according to the RECIST 1.1 criteria) in 40 patients with locally advanced or metastatic disease were recorded. Using a cutoff value of 84 ng/mL, the sensitivity of serum CgA was 67 %, with a specificity of 78 %. Serum CgA levels of patients with different tumor burdens were significantly different. Progressions were observed in 38 out of 122 visits. Using a 28 % increase of serum CgA concentration as the best cutoff value, the sensitivity and specificity were 79 and 86 %, respectively, with positive and negative predictive values of 71 and 90 %, respectively, to determine disease progression. Serum CgA measurement had a modest sensitivity for the diagnosis of non-functioning NETs. However, increases of CgA levels combined with imaging might be helpful in detecting tumor progression in patients with NETs.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Donckier JE, Michel L. Phaeochromocytoma: state-of-the-art. Acta Chir Belg. 2010;110:140–8.

    Article  CAS  PubMed  Google Scholar 

  2. Berruti A, Baudin E, Gelderblom H, Haak HR, Porpiglia F, Fassnacht M, et al. Adrenal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23 Suppl 7:vii131–138.

    Article  PubMed  Google Scholar 

  3. van der Lely AJ, de Herder WW. Carcinoid syndrome: diagnosis and medical management. Arq Bras Endocrinol Metabol. 2005;49:850–60.

    Article  PubMed  Google Scholar 

  4. Vaidakis D, Karoubalis J, Pappa T, Piaditis G, Zografos GN. Pancreatic insulinoma: current issues and trends. Hepatobiliary Pancreat Dis Int. 2010;9:234–41.

    PubMed  Google Scholar 

  5. Bosman F, Carneiro F, Hruban RH, Theise ND. WHO classification of tumours of the digestive system. Lyon: IARC Press; 2010.

    Google Scholar 

  6. Berretta M, Cappellani A, Di Vita M, Berretta S, Nasti G, Bearz A, et al. Biomarkers in neuroendocrine tumors. Front Biosci (Schol Ed). 2010;2:332–42.

    Article  Google Scholar 

  7. Bajetta E, Ferrari L, Martinetti A, Celio L, Procopio G, Artale S, et al. Chromogranin A, neuron specific enolase, carcinoembryonic antigen, and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors. Cancer. 1999;86:858–65.

    Article  CAS  PubMed  Google Scholar 

  8. d’Herbomez M, Do Cao C, Vezzosi D, Borzon-Chasot F, Baudin E, groupe des tumeurs endocrines (GTE France). Chromogranin A assay in clinical practice. Ann Endocrinol (Paris). 2010;71:274–80.

    Article  CAS  Google Scholar 

  9. Massironi S, Rossi RE, Casazza G, Conte D, Ciafardini C, Galeazzi M, et al. Chromogranin A in diagnosing and monitoring patients with gastroenteropancreatic neuroendocrine neoplasms: a large series from a single institution. Neuroendocrinology. 2014;100:240–9.

    Article  CAS  PubMed  Google Scholar 

  10. O’Connor DT, Deftos LJ. Secretion of chromogranin A by peptide-producing endocrine neoplasms. N Engl J Med. 1986;314:1145–51.

    Article  PubMed  Google Scholar 

  11. Zatelli MC, Torta M, Leon A, Ambrosio MR, Gion M, Tomassetti P, et al. Chromogranin A as a marker of neuroendocrine neoplasia: an Italian multicenter study. Endocr Relat Cancer. 2007;14:473–82.

    Article  CAS  PubMed  Google Scholar 

  12. Kocha W, Maroun J, Kennecke H, Law C, Metrakos P, Ouellet JF, et al. Consensus recommendations for the diagnosis and management of well-differentiated gastroenterohepatic neuroendocrine tumours: a revised statement from a Canadian national expert group. Curr Oncol. 2010;17:49–64.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Portela-Gomes GM, Stridsberg M. Selective processing of chromogranin A in the different islet cells in human pancreas. J Histochem Cytochem. 2001;49:483–90.

    Article  CAS  PubMed  Google Scholar 

  14. Laslop A, Doblinger A, Weiss U. Proteolytic processing of chromogranins. Adv Exp Med Biol. 2000;482:155–66.

    Article  CAS  PubMed  Google Scholar 

  15. Stridsberg M, Eriksson B, Oberg K, Janson ET. A comparison between three commercial kits for chromogranin A measurements. J Endocrinol. 2003;177:337–41.

    Article  CAS  PubMed  Google Scholar 

  16. Arnold R, Wilke A, Rinke A, Mayer C, Kann PH, Klose KJ, et al. Plasma chromogranin A as marker for survival in patients with metastatic endocrine gastroenteropancreatic tumors. Clin Gastroenterol Hepatol. 2008;6:820–7.

    Article  CAS  PubMed  Google Scholar 

  17. Nehar D, Lombard-Bohas C, Olivieri S, Claustrat B, Chayvialle JA, Penes MC, et al. Interest of chromogranin A for diagnosis and follow-up of endocrine tumours. Clin Endocrinol (Oxf). 2004;60:644–52.

    Article  CAS  Google Scholar 

  18. Janson ET, Holmberg L, Stridsberg M, Eriksson B, Theodorsson E, Wilander E, et al. Carcinoid tumors: analysis of prognostic factors and survival in 301 patients from a referral center. Ann Oncol. 1997;8:685–90.

    Article  CAS  PubMed  Google Scholar 

  19. Nobels FR, Kwekkeboom DJ, Coopmans W, Schoenmakers CH, Lindemans J, De Herder WW, et al. Chromogranin A as serum marker for neuroendocrine neoplasia: comparison with neuron-specific enolase and the alpha-subunit of glycoprotein hormones. J Clin Endocrinol Metab. 1997;82:2622–8.

    CAS  PubMed  Google Scholar 

  20. Jensen KH, Hilsted L, Jensen C, Mynster T, Rehfeld JF, Knigge U. Chromogranin A is a sensitive marker of progression or regression in ileo-cecal neuroendocrine tumors. Scand J Gastroenterol. 2013;48:70–7.

    Article  CAS  PubMed  Google Scholar 

  21. Wang YH, Yang QC, Lin Y, Xue L, Chen MH, Chen J. Chromogranin A as a marker for diagnosis, treatment, and survival in patients with gastroenteropancreatic neuroendocrine neoplasm. Medicine (Baltimore). 2014;93:e247.

    Article  Google Scholar 

  22. Tateishi K, Kitayama N, Matsuoka Y, Funakoshi A. Comparison of chromogranin A and pancreastatin levels in plasma of patients with pancreatic islet cell tumor. Life Sci. 1995;57:889–95.

    Article  CAS  PubMed  Google Scholar 

  23. Moattari AR, Deftos LJ, Vinik AI. Effects of sandostatin on plasma chromogranin-A levels in neuroendocrine tumors. J Clin Endocrinol Metab. 1989;69:902–5.

    Article  CAS  PubMed  Google Scholar 

  24. Igaz P, Mullner K, Hargitai B, Igaz I, Tombol Z, Racz K, et al. Marked chromogranin A elevation in a patient with bilateral adrenal incidentalomas, and its rapid normalization after discontinuation of proton pump inhibitor therapy. Clin Endocrinol (Oxf). 2007;67:805–6.

    Article  Google Scholar 

  25. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–47.

    Article  CAS  PubMed  Google Scholar 

  26. Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC. Tumours of the lung, pleura, thymus and heart. World Health Organization classification tumours. Pathology and genetics. Lyon: IARC Press; 2004.

    Google Scholar 

  27. Ferolla P, Faggiano A, Mansueto G, Avenia N, Cantelmi MG, Giovenali P, et al. The biological characterization of neuroendocrine tumors: the role of neuroendocrine markers. J Endocrinol Invest. 2008;31:277–86.

    Article  CAS  PubMed  Google Scholar 

  28. Lawrence B, Gustafsson BI, Kidd M, Pavel M, Svejda B, Modlin IM. The clinical relevance of chromogranin A as a biomarker for gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab Clin North Am. 2011;40:111–34. viii.

    Article  CAS  PubMed  Google Scholar 

  29. Stivanello M, Berruti A, Torta M, Termine A, Tampellini M, Gorzegno G, et al. Circulating chromogranin A in the assessment of patients with neuroendocrine tumours. A single institution experience. Ann Oncol. 2001;12 Suppl 2:S73–77.

    Article  PubMed  Google Scholar 

  30. de Herder WW. Biochemistry of neuroendocrine tumours. Best Pract Res Clin Endocrinol Metab. 2007;21:33–41.

    Article  CAS  PubMed  Google Scholar 

  31. Borglum T, Rehfeld JF, Drivsholm LB, Hilsted L. Processing-independent quantitation of chromogranin A in plasma from patients with neuroendocrine tumors and small-cell lung carcinomas. Clin Chem. 2007;53:438–46.

    Article  CAS  PubMed  Google Scholar 

  32. Abou-Saif A, Gibril F, Ojeaburu JV, Bashir S, Entsuah LK, Asgharian B, et al. Prospective study of the ability of serial measurements of serum chromogranin A and gastrin to detect changes in tumor burden in patients with gastrinomas. Cancer. 2003;98:249–61.

    Article  CAS  PubMed  Google Scholar 

  33. Chan JA, Stuart K, Earle CC, Clark JW, Bhargava P, Miksad R, et al. Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumors. J Clin Oncol. 2012;30:2963–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgments

We are highly thankful to the patients for their invaluable participation, as well as to the radiology and laboratory staff.

Compliance with ethical standards

ᅟ

Conflicts of interest

None

Ethics approval

The study involved human participants and was approved by the ethical committee of the Peking Union Medical College Hospital. All participants provided a written informed consent. The study was conducted in accordance with the Declaration of Helsinki.

Author information

Authors and Affiliations

  1. Division of Medical Oncology, Peking Union Medical College Hospital, Beijing, China

    Yuejuan Cheng, Zhao Sun, Chunmei Bai, Changting Meng & Hongyan Ying

  2. Department of Biostatistics, Peking University Clinical Research Institute, Beijing, China

    Xiaoyan Yan & Ran Qin

Authors
  1. Yuejuan Cheng
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Zhao Sun
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Chunmei Bai
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Xiaoyan Yan
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ran Qin
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Changting Meng
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Hongyan Ying
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Chunmei Bai.

Additional information

Yuejuan Cheng and Zhao Sun contributed equally to this study.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Cheng, Y., Sun, Z., Bai, C. et al. Serum chromogranin A levels for the diagnosis and follow-up of well-differentiated non-functioning neuroendocrine tumors. Tumor Biol. 37, 2863–2869 (2016). https://doi.org/10.1007/s13277-015-4114-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-015-4114-7

Keywords

Search

Navigation